Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Brief Report

Drive-Through Anticoagulation Clinic During the COVID-19 Pandemic

Jean Giver, Amy L. Dunn, Amanda Sankar, Joseph Stanek, Kay Monda, Joan Canini, Bryce A. Kerlin, Vilmarie Rodriguez

Keywords: anticoagulation management COVID-19 pandemic drive-through clinic point-of-care monitoring

ABSTRACT

An innovative approach to anticoagulation management during the COVID-19 pandemic was used at our center that allowed patients to stay in their vehicle while our anticoagulation advanced practice registered nurse obtained blood for point-of-care international normalized ratio (INR) testing while education and counseling were completed. A significant improvement in the median percentage of INR within the therapeutic range was observed among the patients who used the drive-through clinic. A small group of patients improved compliance to anticoagulation monitoring. Clinical care models, such as this clinic approach may improve patient compliance and adherence to anticoagulation beyond the pandemic needs.

© 2021 Elsevier Inc. All rights reserved.

Introduction

Given the rapid spread of the SARS-CoV-2 virus, referred to hereafter as the COVID-19 virus, and its detrimental effects on global health, the World Health Organization declared the COVID-19 outbreak a global pandemic on March 11, 2020.1 The highly contagious nature of this virus has created major challenges for the medical care of patients. Patients with preexisting chronic health conditions, such as cardiovascular diseases, have a higher risk for severe COVID-19 infection.2 Safe clinical care that can provide strict measures to prevent COVID-19 exposure and illnesses is required in this high-risk patient population. A significant proportion of our anticoagulation program consists of pediatric and adult patients with congenital heart disease (CHD) on long-term warfarin anticoagulation. This patient population requires close attention to their anticoagulation management with frequent international normalized ratio point-of-care (POC/INR) monitoring through home monitoring with a POC device, visits to a local outpatient laboratory, or visits to an anticoagulation clinic. For those individuals who rely on anticoagulation clinic INR/POC testing, access to health care can be hindered during a pandemic due to decreased access to appointments or fear of potential exposure to infection.

Expert panels have advocated for the creation of innovative approaches to provide safe patient care while maintaining precautions against COVID-19 spread.3-7 Several groups have published the concept and experience of using a drive-through clinic for anticoagulation monitoring and management.8-11 There are limited data on how this model of care can impact anticoagulation management as measured by quality of anticoagulation management (% INR in therapeutic range [TR]) and compliance. In response to the COVID-19 pandemic, our anticoagulation program implemented a drive-through anticoagulation clinic to provide the option for patients and families to stay in their vehicles while having a POC/INR performed. The main objectives of this study were as follows:

1. to assess the degree of compliance to anticoagulation management pre- and post-drive-through clinic;
2. to assess time in TR (TTR), percentage of INR within therapeutic, subtherapeutic, supratherapeutic, and compared with pre- and post-drive-through clinic;
3. to evaluate bleeding and thrombosis complications during the study period; and
4. to assess patient and family satisfaction.

Methods

To provide the best possible care for our patients on chronic warfarin anticoagulation during the COVID-19 pandemic, and following review of the Anticoagulation Forum statements regarding options for INR/POC monitoring during the pandemic,4 our anticoagulation advanced practice registered nurse (APRN) approached the Nationwide Children’s Hospital (NCH) nursing, administration, laboratory leadership, pediatric subspecialties (eg, cardiology, hematology), and surgical subspecialties for support of an anticoagulation drive-through care model. This clinic proposal was evaluated by operational and administrative services to ensure it would meet all regulatory requirements (eg, the Joint Commission, major health insurance payors). This care model did not add an increase in operational costs as it used its own established resources to function. All members involved in this decision agreed that the common goal was to offer other alternatives for care to our patients. Although our anticoagulation program has broad
geographic coverage with many patients having INR/POC monitoring done at home or a local laboratory (n = 308 on long-term warfarin, of which 87% have an underlying cardiac condition requiring anticoagulation [eg, mechanical valve, atrial fibrillation, palliative Fontan], of which 14% have POC devices at home), there is a small group of patients (n = 20) who live locally near our medical center and come to the NCH anticoagulation clinic for INR/POC monitoring. Full institutional review board submission and approval was obtained before clinical data review and analysis.

The drive-through anticoagulation clinic was located near the hospital entrance where families could park their vehicles for a few minutes without disrupting traffic flow. The anticoagulation clinic operated Mondays, Wednesdays, and Thursdays from 8 AM to 12:00 PM and 1 and 3 PM. Up to 16 patients (including in-person visits at the office) per day could be seen by the APRN. Appointments for the drive-through clinic were scheduled days in advance with families choosing this care option. A cart with medical supplies, including the POC/INR machine, was maintained inside the building. Cart and devices were cleaned regularly as per organizational infection control policies. Quality control was also performed for the INR/POC monitoring device as per manufacturer and organizational recommendations.

Patients were screened for COVID-19–related symptoms before their appointment and were encouraged to stay in their vehicles wearing a mask before being approached by the nurse provider. The anticoagulation nurse wore gloves, a facemask, and eye protection. Vital signs were performed before the finger stick. Once POC/INR was performed, results were shared with the patient/family and a written calendar with warfarin dosing recommendations was also provided. Once the clinic was completed for the day, the cart with medical supplies was returned to the anticoagulation nurse’s office and documentation of INR results, and treatment recommendations were entered into the electronic medical record (EMR). Future appointments were scheduled for the patients and families and communicated via phone or through their EMR provider—patient communication secure link.

A retrospective chart review of patients on warfarin therapy who used the drive-through anticoagulation clinic from April 1 through August 31, 2020, was conducted. Patients using the drive-through clinic were identified using a secure patient list kept by the anticoagulation nurse. Patient demographics, underlying diagnosis, and therapeutic INR range were reviewed. Dates and values for INR, percentage of INR within TR, subtherapeutic, and supratherapeutic INR, and degree of compliance with anticoagulation monitoring (at least documentation of 1 INR measured per patient per month) and number of patient visits were collected 6 months before the anticoagulation drive-through clinic and compared with the results obtained after implementation of the drive-through clinic. Clinical outcomes such as thrombosis and bleeding complications were abstracted from the medical records. A standardized institutional approved patient satisfaction survey was provided to each patient. The surveys were collected during patients’ follow-up visits.

Data were summarized descriptively, and comparisons between pre- and post–drive-through clinics were done using Wilcoxon signed-rank tests. Compliance and TTR estimate pre- and postclinic were presented as medians and 95% confidence intervals (CI). P values < 0.05 were considered statistically significant. Analyses were completed using GraphPad Prism software, version 9 (GraphPad Software, San Diego, CA).

### Results

Seventeen patients were evaluated in our drive-through clinic during the study period. Fifty-eight percent were male (n = 10) with a median age of 15 years (range: 3–54; Table 1). Primary indication for warfarin therapy included tricuspid valve replacement (n = 1), mitral valve (n = 5), aortic valve (n = 4), Fontan (n = 5), atrial fibrillation (n = 1), and deep vein thrombosis (n = 1). Median TTR was 60.1% (range: 21.1%–89.2%) with a median cumulative time of anticoagulation of 3.3 years (range: 0.2–6.1 years). Overall compliance pre- and the post–drive-through clinic were similar: median compliance was 100% at both time points (P = 0.16; Figure 1). Five of 6 patients who had compliance <90% achieved an improvement with the drive-through clinic (Figure 1). The median percentage of INR within TR improved significantly with the drive-through clinic from a median of 50% to a median of 80% post-drive-through clinic (P = 0.0103; Figure 2). No bleeding or thrombosis complications were observed. Patients and families reported 100% to agree or strongly agree to the survey questions assessing their satisfaction with the drive-through care approach (Table 2). Some of the families/patients’ comments were as follows: “The drive-up coumadin clinic is very convenient and feels safest during the pandemic. Thank you to our NCH team!” “I like the drive-thru thing. It’s easy and quick.” “The curbside service is a great and easy way of seeing patients for quick service without waiting in a waiting area. Has easy access and the patients are more at ease.” “Keep this clinic outside when possible. Love it.”

### Discussion

The COVID-19 pandemic has forced medical institutions to create innovative ways to provide services for patients’ care following the Centers for Disease Control and Prevention recommendations to prevent the spread of the SARS-CoV-2 virus. The state of Ohio, like many other states in the United States, had been negatively affected by this pandemic, with slightly more than 1 million individuals infected with the virus and more than 20,000 deaths reported by the summer 2021. Guidance on how to manage patients on chronic warfarin therapy during the pandemic was formulated by the Anticoagulation Forum including drive-through clinic testing, home monitoring, extending INR/POC testing to longer intervals in patients with stable therapeutic INR (6–12 weeks), consider switching to a direct oral anticoagulant, and implement telehealth services. Direct oral anticoagulants are contraindicated in patients with mechanical

| Table 1 | Patient Characteristics |
|---------|-------------------------|
| Characteristic | N (%) |
| Total no. of patients | 17 |
| Male sex | 10 (59) |
| Median age (years) | 15 (range: 3–54) |
| Pediatrics (age ≤ 18 years) | 10 (59); median 9 (range: 3–18) |
| Adults | 7 (41); median 29 (range: 19–54) |
| Indications for anticoagulation |  |
| Mitral valve | 5 (29) |
| Fontan | 5 (29) |
| Aortic valve | 4 (24) |
| Atrial fibrillation | 1 (6) |
| DVT | 1 (6) |
| Tricuspid valve | 1 (6) |
| INR goal |  |
| 1.5–2.5 | 5 (29) |
| 2.0–3.0 | 11 (65) |
| 2.2–3.5 | 1 (6) |
| Median % time in therapeutic range | 60.1% (range: 21.1–89.2) |
| Median cumulative time of anticoagulation | 3.3 years (range: 0.2–6.1) |

DVT = deep vein thrombosis; INR = international normalized ratio.
heart valves and the need to keep a therapeutic INR, crucial to prevent thrombosis complications oftentimes require POC/INR monitoring.20-25 The physical presence of the patient is a requirement to obtain POC/INR evaluation and can be the principal barrier for patients who feel apprehensive about coming to an anticoagulation clinic during a pandemic. Thus, an anticoagulation drive-through approach to warfarin management can minimize potential exposure to the COVID-19 virus and improve patient compliance with their anticoagulation care.5-11

Anticoagulation programs driven by pharmacists and dedicated APRNs with physician support have demonstrated improved outcomes in pediatric and adult patients receiving anticoagulation.15-19 Our anticoagulation program was established in 2013 and is led by physician and APRNs, with additional clinical registered nursing to support comprehensive care to nearly 300 patients (70.5% adults) on chronic warfarin therapy. With the onset of the COVID-19 pandemic, outpatient care visits, elective surgical procedures, and hospitalizations decreased. This allowed some flexibility for our anticoagulation advanced nurse practitioner to develop and establish a process of how to schedule and see patients. The availability of anticoagulation clinic appointments and the close physical proximity to the clinic made it possible to provide care for the group of patients who chose the drive-through option for their anticoagulation management.

The degree of compliance and TTR are essential for the prevention of thrombosis and bleeding complications.26-29 The patients who used the drive-through clinic had very good compliance to anticoagulation monitoring at baseline, and their compliance did not change after the implementation of the drive-through clinic. Figure 1 demonstrates improvement in compliance to anticoagulation monitoring compared with the baseline pre-pandemic and after implementation of the drive-through clinic. Patient 8 was lost to follow-up and began attending our anticoagulation clinic right before implementation of the drive-through clinic. Patients 8 and 9 preferred the drive-through care model (eg, easy and quick).

Figure 1. Compliance with the drive-through clinic. Patients 7, 8, 9, 12, and 15 demonstrated improvement in their compliance to anticoagulation monitoring compared with the baseline pre-pandemic and after implementation of the drive-through clinic. Patient 8 was lost to follow-up and began attending our anticoagulation clinic right before implementation of the drive-through clinic. Patients 8 and 9 preferred the drive-through care model (eg, easy and quick).

![Compliance with the drive-through clinic. Patients 7, 8, 9, 12, and 15 demonstrated improvement in their compliance to anticoagulation monitoring compared with the baseline pre-pandemic and after implementation of the drive-through clinic. Patient 8 was lost to follow-up and began attending our anticoagulation clinic right before implementation of the drive-through clinic. Patients 8 and 9 preferred the drive-through care model (eg, easy and quick).](image1)

Figure 2. Percentage of international normalized ratio (INR) in therapeutic range (TR) pre- and post-drive-through anticoagulation clinic for each patient. Patient 8 did not have regular INR data points to calculate %TR pre-drive-through clinic compared with the rest of the patients because the patient was lost to follow-up until starting to attend our clinic right before the drive-through clinic implementation. Median time of INR in TR pre-pandemic 50% (95% confidence interval [CI]: 33%–67%) and post-drive-through clinic 80% (95% CI: 57%–100%), P = 0.0103.

![Percentage of international normalized ratio (INR) in therapeutic range (TR) pre- and post-drive-through anticoagulation clinic for each patient. Patient 8 did not have regular INR data points to calculate %TR pre-drive-through clinic compared with the rest of the patients because the patient was lost to follow-up until starting to attend our clinic right before the drive-through clinic implementation. Median time of INR in TR pre-pandemic 50% (95% confidence interval [CI]: 33%–67%) and post-drive-through clinic 80% (95% CI: 57%–100%), P = 0.0103.](image2)
not decrease with the drive-through clinic. In fact, 5 patients observed an increase in compliance with the drive-through clinic (Figure 1). The major impact observed with the use of the clinic was a significant improvement in the median percentage of INR within TR (median pre 50% vs median post of 80%) and overall patient satisfaction with this model of care as was evident by the results of the patient survey and feedback (Table 2). Our study is perhaps one of the few that documented patient outcomes with this care model (Table 3). Other programs implemented a similar approach in larger anticoagulation programs or satellite clinics; however, their analyses are primarily patient satisfaction and improved access to care.

There are several limitations to our model of care and this report. First, we were only able to provide this option of care to families with vehicles who lived close to our medical center and were willing to come as a drive-through appointment. We lacked the staff resources to provide drive-through anticoagulation clinics outside our medical facility. In addition, the COVID-19 pandemic has had a negative impact on the nation’s economy; therefore, a lack of secure financial support could have affected access to care for some of our patients. Our social services program provides financial support for families in need of transportation for medical appointments. Patients living farther away from NCH did not have the option of a drive-through clinic and had to rely on home POC monitoring or local laboratories. The number of patients who used this model of care was small and might not be a true representation of our anticoagulation patient population. Despite the small sample size, we were able to demonstrate improvement in their anticoagulation management as measured by the percentage of INRs within TR.

Although the drive-through anticoagulation clinic had to close after patient and medical providers’ pandemic restrictions were lifted, our team and institutional leadership will reassess the need

---

Table 2
Summary Responses Patient Satisfaction Survey

| Question                                                                 | Strongly Disagree | Disagree | Somewhat Agree | Agree | Strongly Agree | Not Applicable |
|-------------------------------------------------------------------------|-------------------|----------|----------------|-------|----------------|----------------|
| I am satisfied with the scheduling and registration process.            | —                 | —        | —              | —     | 13 (100%)      | —              |
| All staff I encountered introduced themselves and made me feel welcome. | —                 | —        | —              | 1 (8%)| 12 (92%)       | —              |
| The medical staff showed concern for myself and/or my child.           | —                 | —        | 1 (8%)         | 12 (92%)|                | —              |
| I felt involved/informed of the decisions made by the medical team.     | —                 | —        | 2 (15%)        | 11 (85%)|                | —              |
| The plan of care, testing, and procedures were explained to me in a manner in which I understood. | —                 | —        | 2 (15%)        | 11 (85%)|                | —              |
| I received discharge instructions and was given the opportunity to ask questions. | —                 | —        | —              | 12 (92%)| 1 (8%)         | —              |
| I was kept informed of delays throughout my visit.                     | —                 | —        | 1 (8%)         | 9 (69%)| 3 (23%)        | —              |
| Overall, the facilities were clean and comfortable.                    | —                 | —        | —              | 11 (85%)| 2 (15%)        | —              |
| I was satisfied with the courtesy of all staff encountered during the visit. | —                 | —        | —              | 13 (100%)|                | —              |
| Overall, my needs were met and I would recommend others to Nationwide Children’s Hospital. | —                 | —        | —              | 13 (100%)|                | —              |

---

Table 3
Literature Synopsis COVID-19 Drive-Through-Anticoagulation Clinics

| Study           | Methods/findings                                                                 | Population/generalizability | Study Implications                                                                 | Impact                                                                 | Contrast to Our Report                                                                 | Recommendations                                                                 |
|-----------------|----------------------------------------------------------------------------------|------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Zobeck et al5   | Cross-sectional cohort survey to assess drive up vs in-office clinic; 46.6% preferred drive up clinic; Avg. monthly visits improved or remained steady during pandemic | Rural anticoagulation clinic | Provided another option to anticoagulation clinic access for patients; Improved access to care during pandemic; No increase in cost (used existing resources) | 25% of patients reported barriers to accessing care due to COVID-19; 59% reported desire to continue accessing care through drive-through clinic | Similar patient satisfaction; No increased in operational cost; Authors reported their consideration to continue this model for patient care | Authors plan to study and publish feasibility and outcomes |
| Bookani et al7  | Multistep description on how authors’ drive-through clinic was implemented       | Three anticoagulation clinics with 2,000 patients total, Illinois suburbs, Pharmacy led | Clinical outcomes and feasibility not published yet | Large anticoagulation program covering 3 clinics; Unknown if proposed model was feasible; No patient outcomes or satisfaction measures | Authors plan to study and publish feasibility and outcomes | |
| Truong et al8   | Commentary. Description drive-through clinic                                     | Pharmacy led program; Average age 67.5 years | Able to sustain quality of anticoagulation as measured by %TTR | 80 patients per week; Able to sustain %TTR >80% | Large weekly patient volume; Improved patients’ satisfaction; Able to sustain quality of anticoagulation | |
| Alhmoud et al9  | Two-month report of 515 patients                                                  | Al Wakra Hospital (Qatar), Pharmacy led; >300 patients excluding pediatrics and pregnant females | Provided another means to anticoagulation clinic access; Patient no-show rates decreased from 56% pre-pandemic to 9.5% with drive-through care model | No outcome measures such as quality of anticoagulation care as measured %TTR or % in therapeutic range | Plan to use text messaging (eg, WhatsApp and Viper) to improve communication with patients | |

TTR = time to therapeutic range.
to reinstate this model of care, especially due to concerns with the transmissibility of the COVID-19 delta variant and its potential detrimental effects to access of care by some patients in our anticoagulation program. In conclusion, the drive-through anticoagulation clinic during the COVID-19 pandemic allowed patients to access care from their vehicle. A subgroup of patients improved compliance with anticoagulation monitoring. The median percentage of INR within TR improved significantly after implementation of the drive-through clinic. Innovative approaches such as this clinic may improve patient compliance and adherence to anticoagulation beyond the pandemic patient needs.

References

1. World Health Organization; Accessed 1 May 2021, https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
2. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020;75(18):2352-2371.
3. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow up. Am J Cardiol. 2020;72(23):2950-2973.
4. Anticoagulation Forum. Managing anticoagulation during COVID-19 pandemic: frequently asked questions; Accessed 1 May 2021, https://acforum-excellence.org/Resource-Center/resourcelist/1444-2020-03-17-124028.pdf. 2020.
5. Kow CS, Sunter W, Bain A, Zaidi STR, Hassan SS. Management of outpatient warfarin therapy amid COVID-19 pandemic: a practical guide. Am J Cardiovasc Drugs. 2020;20:301-309.
6. Poli D, Tosetto A, Palareti G, et al. Managing anticoagulation in the COVID-19 era between lockdown and reopening phases. Intern Emerg Med. 2020;15:783-786.
7. Barnes GD, Burnette A, Allen A, et al. Thromboembolism and anticoagulation therapy during COVID-19 pandemic: interim clinical guidelines from the anticoagulation forum. J Thromb Thrombolysis. 2020;50:72-81.
8. Bookani KR, Minga I, Chander M, et al. Drive-Through model for anticoagulation clinics during the COVID-19 pandemic. Clin Appl Thomb Hemost. 2020;26. https://doi.org/10.1177/1076029620947476.
9. Zobeck B, Carson E, MacDowell M, Hunt A, Reeder A. Appointment attendance and patient perception of drive-up INR testing in a rural anticoagulation clinic during the COVID-19 pandemic. J Am Coll Pharm. 2021;4(1):459-464.
10. Truong L, Whitefield K, Nickerson-Troy J, Francotte K. Drive-thru anticoagulation clinic: can we supersize your care today? J Pharm Assoc. 2021;61:665-667.
11. Almhoude E, Abdelsamad O, Soaly E, El Enany R, Elewa H. Anticoagulation clinic drive-up service during COVID-19 pandemic in Qatar. J Thromb Thrombolysis. 2021;51:297-300.
12. Centers for Disease Control and Prevention. Guidance for COVID-19; Accessed 1 May 2021. 2021. https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html.
13. Ohio Department of Health. Coronavirus (COVID-19); Accessed August 3, 2021. 2021. https://wwwcdc.gov/coronavirus/2019-ncov/communication/guidance.html. Ohio.gov.
14. Bridgen ML. Oral anticoagulant therapy: practical aspects of management. Postgrad Med. 1996;99(6):81-102.
15. Newhall F, Savoia H, Campbell J, Monagle P. Anticoagulation clinics for children achieve improved warfarin management. Thromb Res. 2004;114:5-9.
16. Jones S, Newhall F, Manias E, Monagle P. Assessing outcome measures of oral anticoagulation management in children. Thromb Res. 2011;127:75-80.
17. Faircloth JM, Miner KM, Alsaied T, et al. Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients. J Thromb Thrombolysis. 2017;44:38-47.

18. Murray JM, Hellinger A, Dionne R, et al. Utility of a dedicated pediatric cardiac anticoagulation program: the Boston Children’s Hospital experience. Pediatr Cardiol. 2015;36:842-850.
19. Wray NP, Nieuwlaat R, Clarke NR, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257-3291.
20. Mekaj YH, Mekaj AY, Ducib SB, Mifari EL. New oral anticoagulants: their advantages and disadvantages compared to vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967-977.
21. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schunemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2021;141(suppl 2):75-47S.
22. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206-1214.
23. Carnicelli A. Anticoagulation for valvular heart disease; Accessed 1 May 2021. 2015. https://www.accc.org/latest-in-cardiology/articles/2015/05/18/05/58/anticoagulation-for-valvular-heart-disease.

Jean Giver, PCNP-BC, is with the Division of Hematology/Oncology/Bone Marrow Transplant, Nationwide Children’s Hospital, Columbus, OH. Amy L. Dunn, MD, is with the Division of Hematology/Oncology/Bone Marrow Transplant, Nationwide Children’s Hospital, and Department of Pediatrics, The Ohio State University, Columbus, OH. Amanda Sankar, MD, is with the Division of Hematology/Oncology/Bone Marrow Transplant, Nationwide Children’s Hospital, and Department of Pediatrics, The Ohio State University, Columbus, OH. Joseph Stanek, MS, is with the Division of Hematology/Oncology/Bone Marrow Transplant, Nationwide Children’s Hospital, Columbus OH. Kay Monda, RN, is with the Division of Hematology/Oncology/Bone Marrow Transplant, Nationwide Children’s Hospital, Columbus, OH. Joan Canini, RN, is with the Division of Hematology/Oncology/Bone Marrow Transplant, Nationwide Children’s Hospital, Columbus, OH. Joan Canini, RN, is with the Division of Hematology/Oncology/Bone Marrow Transplant, Nationwide Children’s Hospital, Columbus, OH. Amanda Sankar, MD, is with the Division of Hematology/Oncology/Bone Marrow Transplant, Nationwide Children’s Hospital, and Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH. Vilmarie Rodriguez MD, MS, is with the Division of Hematology/Oncology/Bone Marrow Transplant, Nationwide Children’s Hospital, and the Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, and can be contacted at vilmarie.rodriguez@nationwidechildrens.org.

In compliance with standard ethical guidelines, the authors report no relationships with business or industry that would pose a conflict of interest.

Disclosures: The results of our study were presented at the Hemostasis and Thrombosis Research Society (HTRS) Scientific Symposium, March 11–13, 2021.